LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Legend Biotech Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026
$18.65+0.17 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $7.23B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
28.4%
105M of 370M shares
Institutional holders
218
55 new, 26 sold out
Net institutional buying
9M
In Q2 2026
Insider trades, 12 months
0 buys · 4 sales
Net sold $307.83K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson | 57,996,198 | 15.00% | 13G (passive) amendment | Jun 30, 2026 |
| FMR LLC | 48,294,445 | 13.10% | 13G (passive) amendment | Dec 31, 2025 |
| GenScript Biotech Corporation | 174,497,556 | 47.99% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LEGN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 29,093,899 | 7.87% | $840.23M | +3,397,159 | 0.04% |
| Deerfield Management Company, L.P. (Series C) | 8,137,638 | 2.20% | $235.01M | +450,000 | 2.45% |
| Suvretta Capital Management, LLC | 7,070,000 | 1.91% | $204.18M | −511,029 | 3.73% |
| Hhlr Advisors, Ltd. | 5,984,550 | 1.62% | $172.83M | – | 20.77% |
| BlackRock, Inc. | 4,726,534 | 1.28% | $136.50M | +41,991 | 0.00% |
| Westfield Capital Management Co LP | 4,430,063 | 1.20% | $127.94M | −1,333,412 | 0.42% |
| Assenagon Asset Management S.A. | 3,830,112 | 1.04% | $110.61M | New | 0.07% |
| Goldman Sachs Group Inc | 3,662,315 | 0.99% | $105.77M | +2,198,203 | 0.01% |
| Point72 Asset Management, L.P. | 3,076,124 | 0.83% | $88.84M | −809,893 | 0.10% |
| Kynam Capital Management, LP | 3,001,205 | 0.81% | $86.67M | +1,424,910 | 4.79% |
| Artisan Partners Limited Partnership | 1,559,441 | 0.42% | $45.04M | −695,047 | 0.07% |
| State Street Corp | 1,498,704 | 0.41% | $43.29M | +332 | 0.00% |
| Capital International Investors | 1,420,654 | 0.38% | $41.03M | +772,804 | 0.01% |
| Morgan Stanley | 1,394,531 | 0.38% | $40.27M | +791,284 | 0.00% |
| Soleus Capital Management, L.P. | 1,205,000 | 0.33% | $34.80M | New | 1.20% |
| Davern Capital Partners, LP | 1,191,522 | 0.32% | $34.41M | −123,226 | 5.87% |
| Driehaus Capital Management LLC | 1,158,808 | 0.31% | $33.47M | New | 0.19% |
| Renaissance Technologies LLC | 1,000,200 | 0.27% | $28.89M | +478,400 | 0.04% |
| Ghisallo Capital Management LLC | 1,000,000 | 0.27% | $28.88M | New | 0.57% |
| Matthews International Capital Management LLC | 917,266 | 0.25% | $26.49M | −8,654 | 9.08% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 218 | 105M | 28.4% | 55 / 62 | 78 / 26 | 24M | 15M |
| Q1 2026 | 191 | 96M | 26.0% | 33 / 80 | 49 / 40 | 18M | 9M |
| Q4 2025 | 200 | 88M | 23.8% | 36 / 70 | 64 / 35 | 18M | 14M |
| Q3 2025 | 200 | 84M | 22.7% | 25 / 87 | 55 / 34 | 6M | 7M |
| Q2 2025 | 211 | 85M | 22.9% | 36 / 71 | 86 / 30 | 20M | 22M |
| Q1 2025 | 208 | 87M | 23.4% | 29 / 75 | 80 / 31 | 8M | 21M |
| Q4 2024 | 211 | 99M | 26.9% | 39 / 94 | 52 / 35 | 22M | 14M |
| Q3 2024 | 208 | 92M | 24.7% | 44 / 70 | 70 / 16 | 12M | 7M |
| Q2 2024 | 181 | 92M | 24.9% | 31 / 79 | 50 / 37 | 14M | 9M |
| Q1 2024 | 192 | 88M | 23.7% | 26 / 88 | 59 / 38 | 9M | 9M |
| Q4 2023 | 206 | 87M | 23.6% | 34 / 93 | 58 / 27 | 10M | 9M |
| Q3 2023 | 200 | 86M | 23.3% | 23 / 72 | 69 / 15 | 6M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of LEGN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity OTC Portfolio | 3,709,610 | 1.00% | $68.81M | 0.16% | Jul 31, 2026 |
| Select Pharmaceuticals Portfolio | 2,504,500 | 0.68% | $68.02M | 4.53% | May 31, 2026 |
| Select Health Care Portfolio | 2,000,000 | 0.54% | $54.32M | 0.94% | May 31, 2026 |
| VIP Contrafund Portfolio | 1,888,696 | 0.51% | $54.55M | 0.18% | Jun 30, 2026 |
| Fidelity Emerging Markets Fund | 1,729,100 | 0.47% | $32.07M | 0.30% | Jul 31, 2026 |
| Harbor Small Cap Growth Fund | 1,348,391 | 0.36% | $25.01M | 0.94% | Jul 31, 2026 |
| SMALLCAP World Fund Inc | 1,321,196 | 0.36% | $38.16M | 0.04% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,142,080 | 0.31% | $31.02M | 0.01% | May 31, 2026 |
| iShares Biotechnology ETF | 1,052,686 | 0.28% | $30.40M | 0.33% | Jun 30, 2026 |
| Fidelity Advisor Health Care Fund | 1,019,556 | 0.28% | $18.91M | 0.61% | Jul 31, 2026 |
| Artisan International Small-Mid Fund | 956,356 | 0.26% | $27.62M | 1.09% | Jun 30, 2026 |
| iShares Core MSCI Emerging Markets ETF | 825,168 | 0.22% | $22.41M | 0.01% | May 31, 2026 |
| Fidelity U.S. Equity Central Fund | 727,400 | 0.20% | $21.01M | 0.09% | Jun 30, 2026 |
| VIP Mid Cap Portfolio | 695,600 | 0.19% | $20.09M | 0.21% | Jun 30, 2026 |
| Fidelity China Region Fund | 653,039 | 0.18% | $12.11M | 0.47% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ying Huang | Chief Executive Officer, Director | 238,490 | 0.06% | Jul 2, 2026 |
| Carlos E. Santos | Chief Financial Officer | 19,676 | 0.01% | Sep 23, 2026 |
| Ingrid Zhang | Chief Executive Officer | 1,131,860 | 0.31% | Sep 16, 2026 |
| Alan Bash | Interim CEO | 35,142 | 0.01% | Aug 18, 2026 |
| Tomas J. Heyman | Director | 53,720 | 0.01% | Sep 28, 2026 |
| Corazon (Corsee) D. Sanders | Director | 80,101 | 0.02% | Sep 28, 2026 |
| Peter Salovey | Director | 55,096 | 0.01% | Sep 28, 2026 |
| Patrick John Casey | Director | 69,590 | 0.02% | Sep 28, 2026 |
| Darren Xiaohui Ji | Director | 92,103 | 0.02% | Sep 28, 2026 |
| Li Mao | Director | 65,316 | 0.02% | Sep 28, 2026 |
| Fangliang Zhang | Director | – | – | Mar 18, 2026 |
| Ye Wang | Director | 16 | 0.00% | Mar 18, 2026 |
| Robin Meng | Director | – | – | Mar 18, 2026 |
| Gareth Kung | Director | 31,486 | 0.01% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Corazon (Corsee) D. Sanders Director | Sep 24, 2026 | Award | +20,986 | – | – | 80,101 |
| Tomas J. Heyman Director | Sep 24, 2026 | Award | +20,986 | – | – | 53,720 |
| Li Mao Director | Sep 24, 2026 | Award | +20,986 | – | – | 65,316 |
| Darren Xiaohui Ji Director | Sep 24, 2026 | Award | +28,330 | – | – | 92,103 |
| Patrick John Casey Director | Sep 24, 2026 | Award | +20,986 | – | – | 69,590 |
| Peter Salovey Director | Sep 24, 2026 | Award | +28,330 | – | – | 55,096 |
| Carlos E. Santos Chief Financial Officer | Sep 21, 2026 | Award | +19,676 | – | – | 19,676 |
| Carlos E. Santos Chief Financial Officer | Sep 21, 2026 | Sale | −5,430 | $9.14 | $49.63K | 14,246 |
| Ingrid Zhang Chief Executive Officer | Sep 15, 2026 | Award | +1,131,860 | – | – | 1,131,860 |
| Alan Bash Interim CEO | Aug 14, 2026 | Award | +4,908 | – | – | 35,142 |
| Patrick John Casey Director | Jun 30, 2026 | Sale | −6,000 | $14.80 | $88.80K | 48,604 |
| Ying Huang Chief Executive Officer, Director | Jun 30, 2026 | Gift | −3,382 | – | – | 238,490 |
| Ying Huang Chief Executive Officer, Director | Jun 25, 2026 | Sale | −5,566 | $14.78 | $82.27K | 241,872 |
| Ying Huang Chief Executive Officer, Director | Mar 25, 2026 | Sale | −9,936 | $8.77 | $87.14K | 247,438 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Corazon (Corsee) D. Sanders Director | Sep 29, 2026 | 13,685 | $258.91K | Sep 29, 2026 | Restricted Stock Vesting |
| Ying Huang Former Officer & Director | Sep 22, 2026 | 69,812 | $1.30M | Sep 22, 2026 | Stock Option Exercise |
| Carlos E. Santos Officer | Sep 22, 2026 | 2,715 | $50.85K | Sep 22, 2026 | Restricted Stock Vesting |
| Patrick John Casey Director | Jun 30, 2026 | 3,000 | $88.80K | Jun 30, 2026 | Restricted Stock Vesting |
| Ying Huang Officer, Director | Jun 26, 2026 | 2,783 | $79.02K | Jun 26, 2026 | Restricted Stock Vesting |
| Ying Huang Officer, Director | Mar 26, 2026 | 4,968 | $87.15K | Mar 26, 2026 | Restricted Stock Vesting |
| Jessie Yeung Officer | Mar 26, 2026 | 1,862 | $32.66K | Mar 26, 2026 | Restricted Stock Vesting |
| Ying Huang Officer, Director | Dec 29, 2025 | 64,339 | $1.45M | Dec 26, 2025 | Restricted Stock Vesting |
| Corazon (Corsee) D. Sanders Director | Dec 29, 2025 | 969 | $22.06K | Dec 24, 2025 | Restricted Stock Vesting |
| Ying Huang Officer, Director | Dec 29, 2025 | 61,467 | $1.41M | Dec 24, 2025 | Restricted Stock Vesting |
| Corporation GenScript Affiliate | Nov 17, 2025 | 203,586 | $6.17M | Nov 17, 2025 | See Remarks below |
| Patrick John Casey Director | Sep 26, 2025 | 1,000 | $33.29K | Sep 26, 2025 | Restricted Stock Vesting |
| Ying Huang Officer, Director | Sep 24, 2025 | 1,370 | $45.21K | Sep 24, 2025 | Restricted Stock Vesting |
| Corazon (Corsee) D. Sanders Director | Sep 23, 2025 | 307 | $10.44K | Sep 23, 2025 | Restricted Stock Vesting |
| Ying Huang Officer, Director | Sep 23, 2025 | 1,357 | $46.11K | Sep 23, 2025 | Restricted Stock Vesting |